Tickers

1. Composite Trajectory Verdict

For a pre-revenue clinical-stage biotechnology company, the cash flow statement and balance sheet (liquidity/runway) carry the most weight because operations are funded entirely by financing and occasional licensing proceeds, not product sales.

Composite Trajectory: Mixed

Annual results (2025 vs. 2024) show marked improvement: net income of $22.4M vs. a $69.7M loss (10-K 2025-12-31, Consolidated Statements of Operations), operating cash flow of +$29.6M vs. -$62.3M (10-K 2025-12-31, Consolidated Statements of Cash Flows), and cash plus investments rising to $128.7M from $98.6M (10-K 2025-12-31, Consolidated Balance Sheets). This was driven by a $70M upfront license payment from Servier and significant operating expense reductions (R&D down 35%, G&A down 40% year-over-year). However, the most recent six-month period (H1 2026 vs. H1 2025) shows deterioration: a net loss of $18.9M vs. $46.0M net income (10-Q 2026-06-30, Condensed Statements of Operations), operating cash burn of $18.2M vs. $44.3M provided (10-Q 2026-06-30, Condensed Statements of Cash Flows), and cash plus investments declining to $110.5M from $128.7M (10-Q 2026-06-30, Condensed Balance Sheets vs. 10-K 2025-12-31, Consolidated Balance Sheets). The H1 2025 figures included the one-time $70M license payment; excluding that, operating expenses continued to fall (R&D -27%, G&A -2% YoY), but the cash burn trajectory and declining liquidity are the dominant near-term trends.

2. Red Flags

• Earnings driven by one-time license revenue: FY 2025 net income of $22.4M included $70M license revenue; operating income was only $12.5M (10-K 2025-12-31, Consolidated Statements of Operations). H1 2026 had zero license revenue and a $23.3M operating loss (10-Q 2026-06-30, Condensed Statements of Operations).
• Continuing cash burn: $18.2M used in operating activities in H1 2026 (10-Q 2026-06-30, Condensed Statements of Cash Flows); $29.6M provided in FY 2025 included the $70M upfront payment (10-K 2025-12-31, Consolidated Statements of Cash Flows).
• Declining liquidity: Cash, cash equivalents, and investments fell from $128.7M (Dec 31, 2025) to $110.5M (June 30, 2026) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets).
• Growing accumulated deficit: Increased from -$464.7M (Dec 31, 2025) to -$483.7M (June 30, 2026) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets).
• Impairment charges: $7.3M impairment of right-of-use assets and property/equipment in FY 2025 (10-K 2025-12-31, Consolidated Statements of Operations), with additional impairments noted in Q4 2025 related to subleases (10-Q 2026-06-30, Note 10).
• No product revenue: All revenue to date from licensing; no product sales expected for years (10-K 2025-12-31, MD&A Overview; 10-Q 2026-06-30, MD&A Revenue).
• ATM program minimal proceeds: Only $25M gross ($24.5M net) raised since 2022 (10-K 2025-12-31, MD&A Liquidity; 10-Q 2026-06-30, MD&A Sources of Liquidity).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual GAAP results improved sharply: net income $22.4M in FY 2025 vs. net loss $69.7M in FY 2024 (10-K 2025-12-31, Consolidated Statements of Operations). License revenue of $70M (Servier upfront) accounted for the swing; operating expenses fell 27% to $57.5M from $78.8M, with R&D down 35% to $33.6M and G&A down 40% to $16.6M (10-K 2025-12-31, Consolidated Statements of Operations). The six-month comparison shows a reversal: net loss of $18.9M in H1 2026 vs. net income of $46.0M in H1 2025 (10-Q 2026-06-30, Condensed Statements of Operations), entirely due to the absence of license revenue in 2026. Operating expenses continued to decline in H1 2026 to $23.3M from $28.9M in H1 2025 (R&D -27%, G&A -2%) (10-Q 2026-06-30, Condensed Statements of Operations). Q2 2026 alone showed a net loss of $9.9M vs. $10.6M in Q2 2025, with R&D down 21% but G&A up 14% (10-Q 2026-06-30, MD&A Comparison of three months ended June 30). The trajectory is mixed: underlying cost discipline is improving, but reported profitability is volatile and dependent on non-recurring licensing events.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

FY 2025 operating cash flow turned positive at +$29.6M vs. -$62.3M in FY 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows), boosted by the $70M Servier upfront payment received in March 2025 (10-K 2025-12-31, MD&A Cash flows). H1 2026 operating cash flow was -$18.2M vs. +$44.3M in H1 2025 (10-Q 2026-06-30, Condensed Statements of Cash Flows), with the prior period including the license payment. Investing activities provided $16.4M in H1 2026 (net maturities) vs. -$50.6M used in H1 2025 (net purchases) (10-Q 2026-06-30, Condensed Statements of Cash Flows). Financing activities were negligible in both periods ($32K provided in H1 2026, -$84K used in H1 2025) (10-Q 2026-06-30, Condensed Statements of Cash Flows). Total cash, equivalents, and restricted cash declined from $21.8M (Dec 31, 2025) to $20.0M (June 30, 2026) (10-Q 2026-06-30, Condensed Statements of Cash Flows), while investments fell from $107.7M to $91.3M (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets). The company projects runway into H2 2028 (10-Q 2026-06-30, MD&A Liquidity).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Year-over-year (Dec 31, 2025 vs. Dec 31, 2024): total assets rose to $143.0M from $122.6M; cash plus investments increased to $128.7M from $98.6M; total liabilities fell to $30.8M from $39.4M; stockholders' equity rose to $112.2M from $83.3M; accumulated deficit improved to -$464.7M from -$487.1M (10-K 2025-12-31, Consolidated Balance Sheets). Six-month change (June 30, 2026 vs. Dec 31, 2025): total assets fell to $125.0M from $143.0M; cash plus investments declined to $110.5M from $128.7M; total liabilities decreased to $28.9M from $30.8M; stockholders' equity fell to $96.1M from $112.2M; accumulated deficit worsened to -$483.7M from -$464.7M (10-Q 2026-06-30, Condensed Balance Sheets vs. 10-K 2025-12-31, Consolidated Balance Sheets). Right-of-use assets declined from $9.3M to $8.2M, and non-current lease liability from $15.1M to $13.1M, reflecting lease amortization and impairments (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets). The annual comparison shows strengthening; the interim comparison shows cash consumption and equity erosion.

6. Data Gaps

• Standalone Q1 2026 cash flow statement (only YTD H1 2026 provided in 10-Q 2026-06-30)
• Standalone Q2 2025 cash flow statement (only YTD H1 2025 provided in 10-Q 2025-06-30)
• Full Q3 2025 10-Q financial statements (filing content truncated in provided documents)
• Prior-year quarterly comparatives for 2024 (Q1-Q3 2024 10-Qs not provided)
• Breakdown of "Other income (expense)" components beyond interest income and sublease income (filings describe but do not fully quantify each sub-component quarterly)
• Detailed contractual obligations beyond lease payments (filings state other obligations not reasonably estimable)